Drug Trial Radar · NCT04893187
A Phase 1 Study of SSS17 in Healthy Subjects.
Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
76
Planned (sponsor's estimate)
Start
Jul 26, 2021
Primary completion
Dec 31, 2022
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.Industry
- Sponsor type
- Industry
- Collaborators
- Fifth Affiliated Hospital of Guangzhou Medical University
- First posted
- May 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of single oral administration of 5 mg, 15 mg, 20 mg and 25 mg of SSS17 compared with placebo, and evaluate the efficacy, safety, tolerance, pharmacokinetics and pharmacodynamics of multiple oral administration of 15 mg and 20 mg of SSS17 compared with placebo. In addition, the study will assess the effect of food on the pharmacokinetics of SSS17.
Conditions
- Anemia in Chronic Kidney Diseases
Interventions
SSS17Drug
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
PlaceboDrug
Matched placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: AEsTime frame: Baseline up to Days 15
- Part 1: Maximum plasma concentration (Cmax) of SSS17Time frame: Up to 336 hours post-dose
- Part 1: Area under the concentration-time curve (AUC) of plasma concentration of SSS17Time frame: Up to 336 hours post-dose
- Part 1: Time-to-Cmax (Tmax) of SSS 17Time frame: Up to 336 hours post-dose
- Part 1: Elimination terminal half-life (t1/2) of SSS17Time frame: Up to 336 hours post-dose
- Part 1: . Total amount of SSS17 excreted in urine over 72 hours (Ae0-72)Time frame: Up to 72 hours post-dose
- Part 1: Fraction of SSS17 excretion during each collection interval (Fe0-72)Time frame: Up to 72 hours post-dose
- Part 1: Renal clearance (CLR) of SSS17Time frame: Up to 72 hours post-dose
- Part 2: AEsTime frame: Up to Days 33 or 57
- Part 2: Steady state minimal concentration (Css_min) of SSS17Time frame: Up to Days 33 or 57
- Part 2: Steady state maximum concentration (Css_max) of SSS17Time frame: Up to Days 33 or 57
- Part 2: Steady state average concentration (Css_av) of SSS17Time frame: Up to Days 33 or 57
- Part 2: Area under the concentration-time curve of plasma concentration of SSS17 within the interval of administration after reaching steady state (AUC0-τ)Time frame: Up to Days 33 or 57
- Part 3: Maximum plasma concentration (Cmax) of SSS17Time frame: Up to Days 44
- Part 3: Area under the concentration-time curve (AUC) of plasma concentration of SSS17Time frame: Up to Days 44
- Part 3: Time-to-Cmax (Tmax) of SSS 17Time frame: Up to Days 44
- Part 3: Elimination terminal half-life (t1/2) of SSS17Time frame: Up to Days 44
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.